Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology

• Published in: Neurology Vol. 86; no. 19; p. 1818
• Main Authors: Simpson, David M, Hallett, Mark, Ashman, Eric J, Comella, Cynthia L, Green, Mark W, Gronseth, Gary S, Armstrong, Melissa J, Gloss, David, Potrebic, Sonja, Jankovic, Joseph, Karp, Barbara P, Naumann, Markus, So, Yuen T, Yablon, Stuart A
• Format: Journal Article
• Language: English
• Published: United States 10.05.2016
• Subjects: Blepharospasm - drug therapy; Botulinum Toxins, Type A - therapeutic use; Headache - drug therapy; Humans; Muscle Spasticity - drug therapy; Neurotoxins - therapeutic use; Torticollis - drug therapy
• ISSN: 1526-632X
• DOI: 10.1212/WNL.0000000000002560

To update the 2008 American Academy of Neurology (AAN) guidelines regarding botulinum neurotoxin for blepharospasm, cervical dystonia (CD), headache, and adult spasticity. We searched the literature for relevant articles and classified them using 2004 AAN criteria. Blepharospasm: OnabotulinumtoxinA (onaBoNT-A) and incobotulinumtoxinA (incoBoNT-A) are probably effective and should be considered (Level B). AbobotulinumtoxinA (aboBoNT-A) is possibly effective and may be considered (Level C). CD: AboBoNT-A and rimabotulinumtoxinB (rimaBoNT-B) are established as effective and should be offered (Level A), and onaBoNT-A and incoBoNT-A are probably effective and should be considered (Level B). Adult spasticity: AboBoNT-A, incoBoNT-A, and onaBoNT-A are established as effective and should be offered (Level A), and rimaBoNT-B is probably effective and should be considered (Level B), for upper limb spasticity. AboBoNT-A and onaBoNT-A are established as effective and should be offered (Level A) for lower-limb spasticity. Headache: OnaBoNT-A is established as effective and should be offered to increase headache-free days (Level A) and is probably effective and should be considered to improve health-related quality of life (Level B) in chronic migraine. OnaBoNT-A is established as ineffective and should not be offered for episodic migraine (Level A) and is probably ineffective for chronic tension-type headaches (Level B).